According to ARS, the FDA regulators decided at the time that more data was needed to evaluate the safety of repeated doses of the nasal spray before it could be approved. "Neffy is epinephrine ...

On Friday, the FDA announced the approval of neffy, an epinephrine nasal spray by ARS Pharmaceuticals ... associate director of the Division of Pulmonology, Allergy and Critical Care in the ...

Emergency crews were called to the scene after a semi crashed into a building in West Chicago on Wednesday afternoon. A federal judge is expected to rule on a request to stop President Trump's ...

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...

The FDA just approved a new nasal application for allergy medicine. Pennsylvania law allows for school nurses to train other ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Nasal spray offers an alternative for patients ... this is exactly the response required.” As part of the approval process, the FDA asked Belhaven Biopharma to determine if one dose of Nasdepi ...

Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of seizure clusters (also known as "acute repetitive ...

The recommended dose of Atzumi is 5.2 mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine ...